Skip to content

Posts by Rajesh Tim Gandhi, MD

  • Among patients on supplemental oxygen in the ACTT-1 trial, remdesivir significantly reduced the time to recovery, but, according to Massachusetts General Hospital clinicians, the trial neither demonstrated nor disproved a benefit for sicker or less sick patients.

  • With millions of cases of SARS-CoV-2 infection and nearly 350,000 deaths worldwide due to COVID-19 to date, the need for specific antiviral therapies is imperative. Multiple repurposed or newly developed antiviral treatments have been proposed. Many treatments for COVID-19 have been described in case series and retrospective cohort studies (May 8 FLARE), but few have been tested in a randomized controlled trial (May 11 FLARE). In tonight's FLARE, we review the publication of the Adaptive COVID-19 Treatment Trial-1 (ACTT-1), an RCT that resulted in the emergency use authorization by the U.S. Food and Drug Administration (FDA) for remdesivir (Beigel et al. 2020). 

Biography

Dr. Gandhi is associate professor of Medicine at Harvard Medical School, and director of HIV Clinical Services and Education at Massachusetts General Hospital. He has been actively involved in HIV care and research since 1996. Dr. Gandhi is the site leader of the Massachusetts General Hospital AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit (ACTU) and a member of the AIDS Clinical Trials Group HIV-1 Reservoirs and Eradication Transformative Science Group. He is also the director of the Harvard University Center for AIDS Research (CFAR) Clinical Core. Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, which is an internet-based educational conference series for physicians caring for HIV-infected patients in resource-limited settings. He is also an Associate Editor of Journal Watch Infectious Diseases and Contributing Editor to Journal Watch HIV/AIDS Clinical Care. He is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Dr. Gandhi received his medical degree from Harvard, completed his residency at the Brigham and Women's Hospital, and trained in infectious diseases at Johns Hopkins Hospital. His research interests include clinical trials of immune-based therapies for HIV, HIV reservoirs, and HIV/viral hepatitis coinfections.